Key Stats for Danaher Stock
- Past-Week Performance: -7%
- 52-Week Range: $171 to $243
- Valuation Model Target Price: $282
- Implied Upside: 28.3% over 2.9 years
Value your favorite stocks like Danaher Corporation with 5 years of analysts’ forecasts using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
Danaher stock fell about 7% this week, finishing near the lower end of its recent trading range.
The pullback followed the company’s recent earnings update, where reported results were solid but did not lift near-term expectations.
Selling pressure picked up after CEO Rainer Blair and management reiterated that bioprocessing demand remains soft and that a meaningful recovery is taking longer to materialize than investors had anticipated.
With bioprocessing representing Danaher’s largest growth driver, the lack of near-term acceleration led the market to scale back growth expectations.
Analyst updates reinforced the more measured outlook. Evercore ISI raised its price target to $254 from $250 while maintaining an Outperform rating, signaling confidence in Danaher’s long-term fundamentals but limited near-term upside.
Other firms largely reaffirmed existing targets rather than pushing estimates higher, keeping expectations constrained.
Overall, last week’s decline reflected a recalibration of near-term growth expectations rather than a change in the underlying business.
The stock’s inability to hold post-earnings levels suggests investors are waiting for clearer confirmation that bioprocessing demand is stabilizing before re-rating the shares higher.
See analysts’ growth forecasts and price targets for Danaher Corporation (It’s free) >>>
Is Danaher Undervalued?
Under valuation model assumptions, the stock is modeled using:
- Revenue Growth (CAGR): 5.6%
- Operating Margins: 29.7%
- Exit P/E Multiple: 26.1x
Based on these inputs, the model estimates a target price of $282, implying 28.3% total upside from recent levels over the next 2.9 years.
Over the next year, results are likely shaped by whether bioprocessing demand stabilizes, as this segment has weighed on growth but represents Danaher’s largest earnings upside if customer inventory digestion continues to ease.
Margin expansion depends on mix improvement, with higher utilization across life sciences tools and diagnostics improving fixed-cost absorption and operating leverage.
Danaher appears undervalued at current levels, with future performance driven by a recovery in bioprocessing demand and margin normalization rather than a valuation multiple re-rating.
Estimate a company’s fair value instantly (Free with TIKR) >>>
Value Any Stock in Under 60 Seconds (It’s Free)
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
